Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis

References

• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi:10.1038/s41572-020-0205-x
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156(5):1345–1353 e1344. doi:10.1053/j.gastro.2019.01.002
   PubMed Web of Science ®Google Scholar
• Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-pacific. Am J Gastroenterol. 2019;114(1):107–115. doi:10.1038/s41395-018-0233-2
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:10.1093/ecco-jcc/jjx009
   PubMed Web of Science ®Google Scholar
• Neurath MF, Leppkes M. Resolution of ulcerative colitis. Semin Immunopathol. 2019;41(6):747–756. doi:10.1007/s00281-019-00751-6
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357–1373. doi:10.1016/j.mayocp.2019.01.018
   PubMed Web of Science ®Google Scholar
• Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–997. doi:10.1093/ecco-jcc/jjw053
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e393. doi:10.1053/j.gastro.2013.10.052
   PubMed Web of Science ®Google Scholar
• Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol. 2020;17(6):365–376. doi:10.1038/s41575-020-0293-9
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experience. J Crohns Colitis. 2012;6(2):143–153. doi:10.1016/j.crohns.2011.07.011
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135. doi:10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi:10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020. doi:10.1093/ecco-jcc/jjaa161
   PubMed Web of Science ®Google Scholar
• Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(6):635–643. doi:10.1093/ecco-jcc/jjy004
   PubMed Web of Science ®Google Scholar
• Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2019;15(12):656–665.
   Google Scholar
• Feng J, Chen Y, Feng Q, Ran Z, Shen J. Novel gene signatures predicting primary non-response to infliximab in ulcerative colitis: development and validation combining random forest with artificial neural network. Front Med. 2021;8:678424. doi:10.3389/fmed.2021.678424
   Web of Science ®Google Scholar
• Xu M, Kong Y, Chen N, et al. Identification of immune-related gene signature and prediction of CeRNA network in active ulcerative colitis. Front Immunol. 2022;13:855645. doi:10.3389/fimmu.2022.855645
   PubMed Web of Science ®Google Scholar
• Cortes-Ciriano I, Gulhan DC, Lee JJ, Melloni GEM, Park PJ. Computational analysis of cancer genome sequencing data. Nat Rev Genet. 2022;23(5):298–314. doi:10.1038/s41576-021-00431-y
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67(1):43–52. doi:10.1136/gutjnl-2016-312293
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4(11):e7984. doi:10.1371/journal.pone.0007984
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Dalmer TRA, Clugston RD. Gene ontology enrichment analysis of congenital diaphragmatic hernia-associated genes. Pediatr Res. 2019;85(1):13–19. doi:10.1038/s41390-018-0192-8
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–D612. doi:10.1093/nar/gkaa1074
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2. doi:10.1186/1471-2105-4-2
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786. doi:10.1053/j.gastro.2006.12.038
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. doi:10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Starosvetsky E, Maimon N, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD. Gut. 2019;68(4):604–614. doi:10.1136/gutjnl-2017-315494
   PubMed Web of Science ®Google Scholar
• Ghandadi M, Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. Curr Pharm Des. 2016;22(5):518–526. doi:10.2174/1381612822666151124234417
   PubMed Web of Science ®Google Scholar
• Uciechowski P, Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology. 2020;98(3):131–137. doi:10.1159/000505099
   PubMed Web of Science ®Google Scholar
• Schreiber S, Aden K, Bernardes JP, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354–2366 e2311. doi:10.1053/j.gastro.2021.02.062
   PubMed Web of Science ®Google Scholar
• Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28(5):115327. doi:10.1016/j.bmc.2020.115327
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (Surprise study). Ann Rheum Dis. 2016;75(11):1917–1923. doi:10.1136/annrheumdis-2015-208426
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–1023. doi:10.1016/j.immuni.2019.03.026
   PubMed Web of Science ®Google Scholar
• Shahini A, Shahini A. Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome. J Cell Commun Signal. 2022;17(1):55–74. doi:10.1007/s12079-022-00695-x
   PubMed Web of Science ®Google Scholar
• Zhou L, Sonnenberg GF. Essential immunologic orchestrators of intestinal homeostasis. Sci Immunol. 2018;3(20). doi:10.1126/sciimmunol.aao1605
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68(1):40–48. doi:10.1136/gutjnl-2017-314562
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang S, Wang B, et al. 775b olamkicept, an IL-6 trans-signaling inhibitor, is effective for induction of response and remission in a randomized, placebo-controlled trial in moderate to severe ulcerative colitis. Gastroenterology. 2021;161(2):e28–e29. doi:10.1053/j.gastro.2021.06.038
   Web of Science ®Google Scholar
• Shouval DS, Biswas A, Kang YH, et al. Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology. 2016;151(6):1100–1104. doi:10.1053/j.gastro.2016.08.055
   PubMed Web of Science ®Google Scholar
• Yin Q, Pi X, Jiang Y, et al. An immuno-blocking agent targeting IL-1beta and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice. Inflammation. 2021;44(5):1724–1736. doi:10.1007/s10753-021-01449-4
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–1919. doi:10.1056/NEJMoa1706314
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(Suppl6):vi9–vi22. doi:10.1093/rheumatology/kez350
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–255. doi:10.1038/nrgastro.2013.253
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Pressman S, Blatt A, et al. Infliximab-tumor necrosis factor complexes elicit formation of anti-drug antibodies. Gastroenterology. 2019;157(5):1338–1351 e1338. doi:10.1053/j.gastro.2019.08.009
   PubMed Web of Science ®Google Scholar
• Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543–1588. doi:10.7150/thno.15625
   PubMed Web of Science ®Google Scholar
• Bruno ME, Rogier EW, Arsenescu RI, et al. Correlation of biomarker expression in colonic mucosa with disease phenotype in crohn’s disease and ulcerative colitis. Dig Dis Sci. 2015;60(10):2976–2984. doi:10.1007/s10620-015-3700-2
   PubMed Web of Science ®Google Scholar
• Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55–68. doi:10.1016/j.pharmthera.2008.10.005
   PubMed Web of Science ®Google Scholar
• Zhu F, He H, Fan L, et al. Blockade of CXCR2 suppresses proinflammatory activities of neutrophils in ulcerative colitis. Am J Transl Res. 2020;12(9):5237–5251.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Jayakumar C, Manicassamy S, Ramesh G. CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am J Physiol Renal Physiol. 2013;305(10):F1422–F1427. doi:10.1152/ajprenal.00319.2013
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103. doi:10.1111/j.1365-2222.2012.04014.x
   PubMed Web of Science ®Google Scholar
• Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. Cytokine. 2017;98:71–78. doi:10.1016/j.cyto.2017.02.001
   PubMed Web of Science ®Google Scholar
• Behfar S, Hassanshahi G, Nazari A, Khorramdelazad H. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine. 2018;110:226–231. doi:10.1016/j.cyto.2017.12.010
   PubMed Web of Science ®Google Scholar
• Raghu H, Lepus CM, Wang Q, et al. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis. 2017;76(5):914–922. doi:10.1136/annrheumdis-2016-210426
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016;77:44–49. doi:10.1016/j.cyto.2015.10.008
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Strid H, Isaksson S, et al. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. J Crohns Colitis. 2015;9(1):56–65. doi:10.1093/ecco-jcc/jju008
   PubMed Web of Science ®Google Scholar
• Cappenberg A, Kardell M, Zarbock A. Selectin-mediated signaling-shedding light on the regulation of integrin activity in neutrophils. Cells. 2022;11(8):1310. doi:10.3390/cells11081310
   PubMed Web of Science ®Google Scholar
• Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79(1):181–213. doi:10.1152/physrev.1999.79.1.181
   PubMed Web of Science ®Google Scholar
• Song Y, Yuan M, Xu Y, Xu H. Tackling inflammatory bowel diseases: targeting proinflammatory cytokines and lymphocyte homing. Pharmaceuticals. 2022;15(9):1080. doi:10.3390/ph15091080
   Web of Science ®Google Scholar